Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» ALL
ALL
Takeda's Iclusig shows potential to become standard of care in acute lymphoblastic leukemia subtype
Fierce Pharma
Wed, 02/15/23 - 06:16 pm
Takeda
Iclusig
acute lymphoblastic leukemia
ALL
ASCO
Autolus announces primary endpoint met in FELIX trial, prices public offering
Pharmaphorum
Fri, 12/9/22 - 10:45 am
Autolus
ALL
clinical trials
obe-cel
funding
Kite gets US FDA approval for Tecartus to treat acute lymphoblastic leukemia
Pharmaceutical Business Review
Mon, 10/4/21 - 10:39 am
Kite Pharma
Gilead Sciences
Tecartus
FDA
ALL
acute lymphoblastic leukemia
ASCO21: Gilead sets up first FDA okay for adult ALL with Tecartus data
Pharmaforum
Mon, 06/7/21 - 11:07 am
ASCO 2021
Gilead Sciences
Tecartus
ALL
Novartis Kymriah demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
Pharmaceutical Business Review
Tue, 12/10/19 - 10:06 am
Novartis
Kymriah
CAR-T
DLBCL
ALL
FDA approves Servier's ALL therapy, acquired in Shire deal
BioCentury
Fri, 12/21/18 - 04:09 pm
FDA
SHP663
Servier
ALL
#ASH18: Allogene ticks off a high CR rate for updated off-the-shelf CAR-T pioneer. But getting just the right kind of immunosuppression is crucial
Endpoints
Mon, 12/3/18 - 10:50 pm
ASH 2018
Allogene
CAR-T
ALL
Novartis announces new €78m plant and 450 new jobs to manufacture Kymriah in EU
GoinPharma
Tue, 08/28/18 - 07:58 pm
Novartis
Europe
Kymriah
ALL
acute lymphoblastic leukemia
Will Blincyto's Expanded FDA Approval Open the Door for Wider Use of MRD as a Biomarker or Endpoint?
RAPS.org
Tue, 04/3/18 - 11:04 pm
Amgen
Blincyto
ALL
B-cell precursor ALL
On CAR-T’s Edge, Seattle Researchers Plot to Bypass Novartis Therapy
Xconomy
Tue, 09/19/17 - 08:43 am
CAR-T
Novartis
Seattle Children's
pediatric cancer
ALL
gene therapy